Multivariable analysis of baseline factors (at submission) influencing outcome to systemic BT and factors associated with PFS after CAR-T infusion
| Factors affecting response to BT . | Responder/N . | OR (95% CI) . | P-value . |
|---|---|---|---|
| RBP bridging | |||
| No | 34/134 | 1.00 | .010 |
| Yes | 35/83 | 2.21 (1.21-4.05) | |
| Response last line | |||
| SD/PD | 45/165 | 1.00 | .023 |
| CR/PR | 24/52 | 2.16 (1.11-4.22) | |
| Bulky disease | |||
| No | 55/149 | 1.00 | .045 |
| Yes | 14/68 | 0.49 (0.25-0.98) |
| Factors affecting response to BT . | Responder/N . | OR (95% CI) . | P-value . |
|---|---|---|---|
| RBP bridging | |||
| No | 34/134 | 1.00 | .010 |
| Yes | 35/83 | 2.21 (1.21-4.05) | |
| Response last line | |||
| SD/PD | 45/165 | 1.00 | .023 |
| CR/PR | 24/52 | 2.16 (1.11-4.22) | |
| Bulky disease | |||
| No | 55/149 | 1.00 | .045 |
| Yes | 14/68 | 0.49 (0.25-0.98) |
| Factors affecting response to CAR-T . | Events/N . | HR (95% CI) . | P-value . |
|---|---|---|---|
| LDH at LD | |||
| ≤2ULN | 74/141 | 1.00 | .001 |
| >2ULN | 34/41 | 2.06 (1.34-3.16) | |
| Extra nodal sites | |||
| <3 | 91.160 | 1.00 | .001 |
| ≥3 | 17/22 | 2.51 (1.46-4.32) | |
| BT response | |||
| SD/PD | 68/100 | 1.00 | .012 |
| CR/PR | 40/82 | 0.58 (0.38-0.89) |
| Factors affecting response to CAR-T . | Events/N . | HR (95% CI) . | P-value . |
|---|---|---|---|
| LDH at LD | |||
| ≤2ULN | 74/141 | 1.00 | .001 |
| >2ULN | 34/41 | 2.06 (1.34-3.16) | |
| Extra nodal sites | |||
| <3 | 91.160 | 1.00 | .001 |
| ≥3 | 17/22 | 2.51 (1.46-4.32) | |
| BT response | |||
| SD/PD | 68/100 | 1.00 | .012 |
| CR/PR | 40/82 | 0.58 (0.38-0.89) |
MVA baseline factors associated with response BT: (responder vs nonresponder; CR/PR vs SD/PD). ∗Logistic regression, using backward selection (P = .05 inclusion) incorporating the following variables all measured at submission: bridging chemotherapy type, age, sex, ECOG, stage, bulky disease, extra nodal sites, LDH, lymphoma subtype, DHL, refractoriness to previous therapies, response to last line, and ≥3 lines of previous therapy. MVA factors associated with PFS after infusion including BT response (only patients receiving RT/CT/CMT). Variables that remain significant in MVA (backward selection, P = .05 for rejection). Variables included in the MVA: age, sex, ECOG, stage (submission), bulky disease, extra nodal sites (submission), LDH (pre-LD), CRP, low platelets, low lymphocytes, lymphoma subtype, DHL, refractory to previous therapies, response last line, >2 lines previous therapy and response to bridging.